CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced it has discovered an innate mechanism to allosterically modulate the N-methyl-D-aspartate (NMDA) receptor that could prove key to treating a wide range of neuropsychiatric disorders, including Alzheimer’s, schizophrenia, autism, and depression. The research, published in the Journal of Neuroscience, also showed that a proprietary compound developed by SAGE effectively restored behavioral and cognitive function in preclinical studies using this newly discovered approach to target the NMDA receptor.
Help employers find you! Check out all the jobs and post your resume.
